MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia

• Status: Recruiting
• Trial end date: 2022-02-25
• Target enrollment: 0
• Participant gender: Female

Summary

To compare the efficacy of Medroxyprogesterone Acetate with dydrogesterone in patients having endometrial hyperplasia (EH) without atypia.

• Phase: Phase 2/Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Xiaojun Chen
• Treatments: Dydrogesterone; Medroxyprogesterone; Medroxyprogesterone Acetate

Criteria

Inclusion Criteria:

• Pathologically confirmed diagnosis of endometrial hyperplasia without atypia;

• Consent informed and signed;

• Able to follow treatment and take therapy in Obstetrics and Gynecology of Fudan University

Exclusion Criteria:

• Liver disease or liver tumor (benign or malignant)

• Kidney disease or kidney tumor (benign or malignant)

• Other malignancies in reproductive organs

• Breast cancer or other progesterone-dependent tumors

• History of endometrial atypical hyperplasia or endometrial cancer

• Any contradictions against progesterone

• Under treatment of progestin therapy or oral conceptive drugs one month before enrollment.

• Pregnancy or suspicion of pregnancy

• Ask for other treatment